Product Datasheet
Catalog Number |
ADT1220 |
Product Name |
Eptinezumab Research Biosimilar |
Product Description |
Eptinezumab, sold under the brand name Vyepti, is a medication for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion every three months. Eptinezumab-jjmr was approved for use in the United States in February 2020. |
CAS Number |
1644539-04-7 |
Clonity |
Monoclonal |
Target |
CALCA /CALCB[Homo sapiens] |
Alias |
ALD-403, Eptinezumab Research Biosimilar |
Host |
CHO Cells |
Isotype |
IgG1 Kappa |
Size |
100ug,1mg,5mg |
Mechanism of Action |
Eptinezumab is a fully-humanized IgG1 antibody manufactured and designed specifically to bind both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). Studies since 1985 have demonstrated that CGRP levels increase during acute migraine attacks in migraine-suffering patients but normalize after efficacious sumatriptan therapy. Moreover, research has also shown that intravenous administration of CGRP can induce migraine-like attacks in migraine-suffering patients. For all these reasons, the binding of CGRP to interfere with its activity was specifically designed to be the form and mechanism of action for eptinezumab. The binding of eptinezumab to natural endogenous CGRP subsequently interferes with its activities, such as its binding to CGRP receptors, for example. |
Metabolism |
Monoclonal antibody agents like eptinezumab are not expected to generate toxic metabolites as they generally undergo proteolysis to their constituent amino acids. |
Buffer |
Supplied in PBS, PH7.5 |
Concentration |
Batch dependent, please contact our customer service to get the COAs of current batch |
Purity |
>95% as determined by SDS-PAGE |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
This product is shipped in blue ice. |